Table 1 Eligibility criteria based on Population, Interventions, Comparisons, Outcomes, and Study design criteria

Population

Patients with acute myeloid leukemia with mutated TP53 receiving first-line treatments

Intervention

Intensive chemotherapy

Hypomethylating agents as monotherapy

Venetoclax + hypomethylating agents

Outcomes

Primary outcomes:

 Complete remission (CR)

 CR with incomplete hematologic recovery (CRi)

 Any CR (CR/CRi)

 Median overall survival

Secondary outcomes, if available:

 Event-free survival

 Duration of response

 Overall response rate

Study design

Randomized controlled trials

Single-arm trials

Prospective observational studies with n ≥ 20

Retrospective studies with n ≥ 20